Literature DB >> 18972869

[Rational antibiotic therapy of urinary tract infections].

Florian M E Wagenlehner1, Kurt G Naber, Wolfgang Weidner.   

Abstract

Rational antibiotic therapy of urinary tract infections Urinary tract infections (UTI) are frequent infections in the outpatient and nosocomial setting. Generally UTI can be stratified into uncomplicated and complicated infections with respect to treatment options. Uncomplicated UTI are mainly caused by E. coli, whereas complicated UTI exhibit a broader bacterial spectrum with a higher rate of multiresistant uropathogens. On the other hand increasing resistance rates are also found in uncomplicated UTI, e.g. against aminopenicillins, Co-trimoxazol and increasingly also fluoroquinolones. This fact has to be considered in the empirical therapy. Recurrent UTI are frequently found in young, sexually active women, and postmenopausal women. In complicated UTI the complicating factors have to be diagnosed and treated additionally to the antibiotic treatment. If not treated, a severe UTI and urosepsis can develop.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972869

Source DB:  PubMed          Journal:  Med Monatsschr Pharm        ISSN: 0342-9601


  3 in total

1.  Antimicrobial susceptibility patterns of E. coli from clinical sources in northeast Ethiopia.

Authors:  M Kibret; B Abera
Journal:  Afr Health Sci       Date:  2011-08       Impact factor: 0.927

2.  Evaluation of antimicrobial susceptibility of Escherichia coli strains isolated in Rabat University Hospital (Morocco).

Authors:  Nabil Alem; Mohammed Frikh; Abdellatif Srifi; Adil Maleb; Mariama Chadli; Yassine Sekhsokh; Lhoucin Louzi; Azzedine Ibrahimi; Abdelhay Lemnouer; Mostafa Elouennass
Journal:  BMC Res Notes       Date:  2015-08-30

Review 3.  Drug Resistance Patterns of Escherichia coli in Ethiopia: A Meta-Analysis.

Authors:  Kald Beshir Tuem; Abadi Kahsu Gebre; Tesfay Mehari Atey; Helen Bitew; Ebrahim M Yimer; Derbew Fikadu Berhe
Journal:  Biomed Res Int       Date:  2018-05-06       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.